A randomized controlled trial to compare safety and efficacy of inhalational long acting β2 agonist Vilanterol with fluticasone furoate against Salmeterol with fluticasone furoate in adult patients with reversible obstructive airway disease.

This research basically addresses the pressing need for optimized treatment strategies amidst increasing respiratory ailments. This is a comparative study between inhalational long acting β2 agonist Vilanterol with fluticasone furoate against Salmeterol with fluticasone furoate for safety and efficacy. Out of the two Vilanterol being once a daily drug has better adherence to regimen and so we developed the proforma for obtaining the information regarding the safety and efficacy of the drugs in adult patients at the end of 18 months study period. Adult patients (age group 18-60 year) suffering from reversible obstructive airway disease would be selected from pulmonary medicine department of a tertiary care center and would be divided into two groups of 35 patients each and one group will receive Vilanterol with fluticasone furoate while the other will receive Salmeterol with fluticasone furoate and they will be accessed for changes in FEV1 and FVC values , severity  and numbers of respiratory distress and AQI thrice at beginning, at 7 day interval and finally at 4 week interval.